Navigation Links
AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
Date:11/30/2007

WILMINGTON, Del., Nov. 30 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that it has completed enrollment of patients in the ZEST (ZACTIMA Efficacy Study versus Tarceva) study, the first of four Phase III trials for the investigational once-daily oral anti-cancer drug vandetanib. Data from the study is expected in 2008.

ZEST is a randomized, double-blind, multi-center Phase III study to assess the efficacy of vandetanib versus erlotinib in overall survival (OS) and progression-free survival (PFS) in over 1,150 patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) after failure of first-line anti-cancer therapy.

"Non-small cell lung cancer is an area of high unmet medical need, and we hope vandetanib will offer a beneficial new treatment option for people with lung cancer," said Dr. Peter Langmuir, Medical Science Director at AstraZeneca.

ZEST is part of a Phase III clinical trial program to gain a broad understanding of how vandetanib may benefit people with lung cancer.

The other studies are:

-- ZODIAC (vandetanib + docetaxel versus docetaxel alone)

-- ZEAL (vandetanib + pemetrexed versus placebo + pemetrexed); and,

-- ZEPHYR (vandetanib + best supportive care (BSC) versus placebo + BSC).

These studies are currently recruiting patients.

The Phase III program in NSCLC follows results from two Phase II trials where vandetanib was studied either alone or in combination with standard chemotherapy (docetaxel). (1)(2) Vandetanib is also being evaluated as a treatment option in medullary thyroid cancer and has been awarded Food and Drug Administration (FDA) orphan drug status and fast track designation for this indication.

About AstraZeneca

AstraZeneca is a major international health care business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of health care services. It is one o
'/>"/>

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
9. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
10. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
11. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)..., NEW YORK, Dec. 2 Reportlinker.co...vailable in its catalogue: ,, Hemoglobin A1c M...w.reportlinker.com/p0164230/Hemoglobin-A1c-Monitor...ness of affliction and the need for effective ther... a significant market for monitoring the treatment...
(Date:12/2/2009)..., NEW YORK, Dec. 2 Reportlinker.co...vailable in its catalogue: ,, Global Markets ...rtlinker.com/p0166826/Global-Markets-for-Asthma-an...ysis of the global market for medications that tre...e ,, Contains global market forecasts through 2...
(Date:12/2/2009)...ITTLE FALLS, N.J., Dec. 2 /PRNewswire-FirstCall/ -... the results for its first quarter ended October 3... hold a conference call to discuss the results at ...arles M. Diker, Chairman; Andrew A. Krakauer, Pres...dent; Craig A. Sheldon, Senior Vice President, CFO...
Breaking Medicine Technology:Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 2Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 3Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 4Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 5Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 6Reportlinker Adds Hemoglobin A1c Monitoring - Global Market Trends 7Reportlinker Adds Global Markets for Asthma and COPD Drugs 2Reportlinker Adds Global Markets for Asthma and COPD Drugs 3Reportlinker Adds Global Markets for Asthma and COPD Drugs 4Reportlinker Adds Global Markets for Asthma and COPD Drugs 5Reportlinker Adds Global Markets for Asthma and COPD Drugs 6Reportlinker Adds Global Markets for Asthma and COPD Drugs 7Reportlinker Adds Global Markets for Asthma and COPD Drugs 8Reportlinker Adds Global Markets for Asthma and COPD Drugs 9Reportlinker Adds Global Markets for Asthma and COPD Drugs 10Reportlinker Adds Global Markets for Asthma and COPD Drugs 11Cantel Medical Corp. to Hold Conference Call to Discuss Results for its First Quarter Ended October 31, 2009 2New York Personal Injury Attorney Defends Medical Malpractice 55474 1New York Personal Injury Attorney Defends Medical Malpractice 55474 2New York Personal Injury Attorney Defends Medical Malpractice 55474 3Studies show dramatic decline in rheumatoid vasculitis in US veterans 55469 1Studies show dramatic decline in rheumatoid vasculitis in US veterans 55469 2Breakthrough Technology Harnesses Microorganism for Use as Green Bio Pesticide 55467 1Breakthrough Technology Harnesses Microorganism for Use as Green Bio Pesticide 55467 2Breakthrough Technology Harnesses Microorganism for Use as Green Bio Pesticide 55467 3Breakthrough Technology Harnesses Microorganism for Use as Green Bio Pesticide 55467 4Breakthrough Technology Harnesses Microorganism for Use as Green Bio Pesticide 55467 5
...Austria, June 11 /PRNewswire-FirstCall/,-- Iomai C...blication of data,from the company,s positive Phas...e in The Lancet. The study, which analyzed data fr... Iomai patch-based vaccine were,statistically sign...gnificant diarrhea than their counterparts who rec...
...U today,announced that its WaveReady 3000 series h... Inc. as compatible with Brocade-based Storage Are...esting requirements of the,Brocade Data Center Rea...to,foster interoperability in multi-vendor Brocade... that JDSU has successfully completed the Data Cen...
Other Medicine Technology:Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine 2Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine 3Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine 4Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine 5Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine 6Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine 7JDSU WaveReady Receives Brocade Data Center Ready Status for Brocade-Based Storage Area Network (SAN) Infrastructures 2JDSU WaveReady Receives Brocade Data Center Ready Status for Brocade-Based Storage Area Network (SAN) Infrastructures 3
(Date:12/2/2009)...swire-USNewswire/ -- The American Association of P...pin Regional Poison Center in Minneapolis, Minneso...r milestone for the center. The designation by th... among 58 accredited poison centers in the United ...complishment. It means we have met the national st...
(Date:12/2/2009)...swire-USNewswire/ -- In response to a press confe... ," an initiative from the U.S. Anti-Doping Agen...r Responsible Nutrition (CRN), the leading trade a...ustry, issued the following statement: ,, Sta..., "We share the concerns of Travis Tygart (USAD...
(Date:12/2/2009)...ses, study finds , , WEDNESDAY, Dec. 2 (...al rates for advanced lung cancer patients in the ...has found. , Researchers analyzed data on more ...mall cell lung cancer (NSCLC) between 1990 and 200...l Cancer Institute,s Surveillance, Epidemiology an...
(Date:12/2/2009)... unclear, researchers say , , WEDNESDAY,...that enzyme replacement therapy can make a major d...e, a rare illness that affects the kidneys, heart ...o the lack of an enzyme that helps metabolic pathw...boosts the risk for a stroke, heart attack and kid...
(Date:12/2/2009)... Researchers from aroun...ancer research at the annual American Society of H... 4-8, 2009. ,, Throughout the ASH conference, ... including Chief Medical Officer Barton Kamen, M.D...s Hildy Dillon, and Vice President, Research Commu...
Breaking Medicine News(10 mins):Health News:Hennepin Regional Poison Center Designated as an Accredited Poison Control Center 2Health News:CRN Responds to 'Supplement Safety Now' Initiative 2Health News:CRN Responds to 'Supplement Safety Now' Initiative 3Health News:Gains Made in Lung Cancer Survival 2
...Byrd Alzheimer,s Institute Shows Cognitive Activit...Against Memory Loss, TAMPA, Fla., Sept. 12 New r...lifelong activities, only a high level of,mental o...Byrd Institute researchers raised Alzheimer,s mice...
...ad to new drug to treat manic phase of the illness...thDay News) -- The breast cancer drug tamoxifen he...nd works faster than many standard medications use...e this long period before they start to work," exp...
.... 12, 2007 Rice University chemists have discover...ancer drug paclitaxel onto tiny gold spheres. The ...iving cell that literally bristles with the drug. ...e most effective anti-cancer drugs, and many resea...
... Sept. 12 A new, free white paper,details how OSF... has,substantially reduced lift injuries while boo...w lift team department that provides patient trans... Portal, (http://www.safeliftingportal.com ), a pr...
...developed psoriasis at the age of 5; as a teenager...red 70 percent of her body.,Today, her curse is he...l,Psoriasis Foundation, PORTLAND, Ore., Sept. 12 ...y, Sept.,29, at Mission Bay Park. The event featur...
...pt. 12 Psychemedics,Corporation (Amex: PMD ) was...alent Officer, an innovative new book sponsored by...t issues and the growing imperative for,HR leaders...ive approaches to leading,and managing human capit...
Other Medicine News:Health News:Cognitive Activities Protect Against Alzheimer's -- Social and Physical Activities Not Enough 2Health News:Tamoxifen Helps Treat Bipolar Disorder 2Health News:Tamoxifen Helps Treat Bipolar Disorder 3Health News:Taxol bristle ball: a wrench in the works for cancer 2Health News:New Case Study Details How an Illinois Hospital Created a Safe Lifting Team that Dramatically Reduced Injuries, Increased Staff Satisfaction 2Health News:America's Next Top Model Steps up for Psoriasis Awareness 2Health News:Psychemedics Corporation Joins Accenture in Co-Sponsoring Innovative Chief Talent Officer Book 2Health News:Psychemedics Corporation Joins Accenture in Co-Sponsoring Innovative Chief Talent Officer Book 3
Scorpio Posteriorly Stabilized Single Axis Knee
Maxim Primary Knee System
AGC Total Knee System
...paring version which provides the following: Patel...atellas. Precision machined condyles assure precis...ular surface and patella to reduce wear. Constant ...ative change of sizes. Extended and deepened patel...
Medicine Products: